Acrux Limited has released a press release.
FY26 Annual Report and Appendix 4E
Earlier from Acrux
- Investor Presentation - Female Testosterone for HSDD
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Capital Gains Tax exemptions remain in place for Acrux